Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan.
Anticancer Res. 2011 Sep;31(9):3073-7.
The clinical significance of neoadjuvant chemoradiotherapy (NACRT) for potentially resectable esophageal squamous cell carcinoma (ESCC) is unclear.
Patients with clinical stage II-III ESCC were classified into an NACRT group (n=76) and surgery alone group (n=92). The prognosis and the incidence of postoperative complications were retrospectively investigated. The pathological response to NACRT and patient prognosis were also analyzed.
The 5-year survival rate was 47.7% in the surgery alone group and 56.5% in the NACRT group (p=0.4831). The 5-year survival rates of patients in whom NACRT was markedly effective was clearly better than that of the other patients (ineffective/slightly effective: 36.9%, moderately effective: 53.8%, markedly effective: 100%). The incidence of postoperative complications was 31.5% in the surgery alone group and 40.8% in the NACRT group (p=0.2121).
A pathological complete response to NACRT is critical for improving the survival of patients with clinical stageII-III ESCC.
新辅助放化疗（NACRT）对局部可切除食管鳞癌（ESCC）的临床意义尚不清楚。
将临床分期为 II-III 期的 ESCC 患者分为 NACRT 组（n=76）和单纯手术组（n=92）。回顾性调查两组患者的预后和术后并发症发生率。分析 NACRT 的病理反应与患者预后的关系。
单纯手术组的 5 年生存率为 47.7%，NACRT 组为 56.5%（p=0.4831）。NACRT 明显有效的患者 5 年生存率明显高于其他患者（无效/轻度有效：36.9%，中度有效：53.8%，明显有效：100%）。单纯手术组的术后并发症发生率为 31.5%，NACRT 组为 40.8%（p=0.2121）。
NACRT 的病理完全缓解是改善临床 II-III 期 ESCC 患者生存的关键。
